Overview
Adeno-associated virus (AAV) vectors are a versatile technology that can be used for applications in gene therapy. Recent prominent examples include the novel gene therapies Luxturna® to treat a rare form of inherited vision loss, and Zolgensma® to target the genetic root cause of spinal muscular atrophy (SMA). For AAV alone, there are currently over 260 ongoing clinical trials.
Improving the productivity of viral vectors is increasingly important when moving from clinical to commercial phases. In recent years, there has been great progress towards industrialization of the technology but there is still a need to increase efficiency. Supplementing commercial media with performance boosting ingredients offers a versatile and convenient method to achieve this. L-Glutamine dipeptides are proven tools in other cell culture applications but have not been systematically investigated for viral vector production in HEK cells.
In this webinar you will learn how the right choice of glutamine peptide can boost productivity and product quality in viral vector production processes. Our case study shows that supplementation with the dipeptide cQrex
®® GQ resulted in an 87 percent increased AAV8 virus titer and more than 15 percent higher packaging efficiency when used instead of L-glutamine or L-alanyl-L-glutamine. The cQrex
® portfolio of chemically defined, highly pure peptides allows media and bioprocess developers to get the most out of their cells.
As a participant in this webinar you will learn about:
- Trends and challenges in viral vector production
- Benefits and available choice of glutamine peptides
- How different glutamine peptides are metabolized by HEK cells
- How the right choice of glutamine peptide increases viral vector productivity and quality
